Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 Biomarker disease BEFREE CBL0137 decreased the viability of a panel of MLL-r leukemia cell lines (n = 12) and xenograft cells derived from patients with MLL-r acute lymphoblastic leukemia (ALL, n = 3) in vitro with submicromolar IC50s. 31325323 2020
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 GeneticVariation disease BEFREE Infant acute lymphoblastic leukemias (ALL) are rare hematological malignancies occurring in children younger than 1 year of age, most frequently associated with KMT2A rearrangements (KMT2A-r). 31515871 2020
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 GeneticVariation disease BEFREE KMT2A rearrangements are highly pathogenic leukaemic drivers, reflected by the high incidence of KMT2Ar ALL in infants, who carry few leukaemia-associated cooperative mutations. 31705930 2020
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 GeneticVariation disease BEFREE ALL related to prior cytotoxic therapy (t-ALL) appears to be a distinct entity when compared to the de novo ALL, with characteristics including older age at the time of onset, female predominance and leukemia genetics enriched with KMT2A (MLL) gene rearrangement and chromosomes 5/7 abnormalities. 31235377 2019
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 GeneticVariation disease BEFREE We report BU PK data on HSCT conditioning for infants with KMT2A-gene-rearrangement-positive acute lymphoblastic leukemia (MLL-r ALL). 31201644 2019
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 Biomarker disease BEFREE Thus, defining mechanisms underlying MLL-r ALL maintenance is critical for developing effective therapy. 31395602 2019
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 GeneticVariation disease BEFREE Except for one case with biallelic KMT2A (MLL) breaks, all cases analyzed by FISH lacked the most common translocations defining molecular subsets of lymphoblastic leukemia/lymphomas. 30578714 2019
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 GeneticVariation disease BEFREE A few breakpoints detected in the SAR region were mapped within the AF9 region that was previously reported to translocate with the mixed lineage leukaemia (MLL) gene in an acute lymphoblastic leukaemia (ALL) patient. 30646906 2019
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 GeneticVariation disease BEFREE MLL rearrangements are translocation mutations that cause both acute lymphoblastic leukemia and acute myeloid leukemia (AML). 31405949 2019
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 Biomarker disease BEFREE After referral to our clinic, tests of the morphology, immunology, cytogenetics, and molecular biology of his bone marrow led to a diagnosis of MLL-AF4 fusion positive B-cell ALL. 31192927 2019
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 GeneticVariation disease BEFREE Although KMT2A rearrangement is the predominant genetic signature in infantile B-ALL, disease course is heterogenous, behaving more aggressively in younger infants. 30188223 2019
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 Biomarker disease BEFREE Multiple mice engrafted with MLL-r ALL remained disease free for more than 1 year after treatment. 31821784 2019
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 GeneticVariation disease BEFREE However, since this disease is highly represented in the infant and paediatric population, this review will focus on this demographic group and summarise the biological, clinical and epidemiological knowledge on B cell acute lymphoblastic leukaemia of four well characterised subtypes: t(4;11) MLL-AF4, t(12;21) ETV6-RUNX1, t(1;19) E2A-PBX1 and t(9;22) BCR-ABL1. 28819864 2018
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 Biomarker disease BEFREE Frozen/thawed CARCIK-CD19 remained fully functional both in vitro and in an established patient-derived xenograft (PDX) of MLL-ENL rearranged acute lymphoblastic leukemia (ALL). 29641322 2018
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 Biomarker disease BEFREE These combined data demonstrate that panobinostat cross-inhibits multiple epigenetic pathways, ultimately contributing to its highly efficacious targeting of MLL-rearranged ALL. 28690313 2018
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 Biomarker disease BEFREE NRAS mutations were associated with a higher frequency of hyperdiploidy (P = 0.01) and lower frequency of ETV6-RUNX1 (P < 0.01), whereas KRAS mutations were associated with younger age (P < 0.01), a higher frequency of KMT2A rearranged (P < 0.01) but no significant difference if infants with ALL were excluded, and inferior event-free survival (66.6% vs. 80.5%, P = 0.04). 28853218 2018
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 GeneticVariation disease BEFREE Such factors as younger age than 2 years old, MLL/AF4 fusion gene, poor response to prednisone, or no complete remission (CR) on TP3 were poor prognostic parameters in predicting the outcome in childhood ALL with MLL gene rearrangement treated with CCLG-ALL 2008 protocol. 30280786 2018
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 Biomarker disease BEFREE MLL+ALL has a unique gene profile distinguishable from other types of ALL and AML, and should be investigated separately in responses to biological active agents including chemokine inhibitors. 30453100 2018
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 Biomarker disease BEFREE Overall, our data demonstrate that wild-type MLL1 is a regulator of pre-BCR signaling and B cell differentiation and further suggest that targeting its function in pro-B cell ALL may be more broadly effective than previously anticipated. 29351999 2018
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 GeneticVariation disease BEFREE Among the three age groups, older patients more often had higher risk ALL due to T-ALL (32%/25%/9%, P<0.001), KMT2A rearrangements (6%/5%/3%, P<0.001) and higher day 29 residual leukemia for B-lineage (P<0.001), but not T-ALL (P=0.53). 28819280 2018
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 GeneticVariation disease BEFREE Childhood acute lymphoblastic leukaemia (ALL) with MLL rearrangement (MLL-r) is an aggressive disease still associated with a high mortality rate. 29056538 2017
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 Biomarker disease BEFREE Our findings show how amlexanox degrades the resistance of <i>KMT2A/AFF1</i>-positive ALL to TNFα by downregulating S100A6 expression, with immediate potential implications for improving clinical management of <i>KMT2A/AFF1</i>-positive ALL.<i></i>. 28646023 2017
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 GeneticVariation disease BEFREE Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. 27122129 2017
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 Biomarker disease BEFREE In contrast, infant ALL without KMT2A-R is more similar to ALL of older children and survival has improved modestly with intensification of chemotherapy. 27841777 2017
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.300 GeneticVariation disease BEFREE Deregulation of the epigenome is an important pathogenetic mechanism in acute lymphoblastic leukemia (ALL) with lysine (K)-specific methyltransferase 2A rearrangement (KMT2Ar). 27786413 2017